Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:41:45 EDT Mon 14 Oct 2024
Enter Symbol
or Name
USA
CA



Z:BMY - BRISTOL-MYERS SQUIBB CO - http://www.bristolmyers.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BMY - Z1.852.64·52.885.552.69+0.490.96,457.0336,22231,21752.135  52.71  51.938757.645  39.3517:22:41Oct 0315 min RT 2¢

Recent Trades - Last 10 of 31217
Time ETExPriceChangeVolume
17:22:41Z52.670.47682
17:20:36Z52.740.54200
17:18:44Z52.640.4495
17:14:27Z52.5250.3251
17:14:26Z52.59380.39381
17:06:01Z52.650.4555
17:04:38Z52.660.461
17:02:25Z52.65990.459945
17:01:20Z52.640.445
16:49:14Z52.46030.2603200

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-10-03 17:35U:BMYNews ReleaseU.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo(TM) (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
2024-09-30 07:00U:BMYNews ReleasePrime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
2024-09-27 11:06U:BMYNews ReleaseBristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
2024-09-26 21:05U:BMYNews ReleaseU.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY(TM) (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
2024-09-18 06:59U:BMYNews ReleaseNew Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
2024-09-15 08:55U:BMYNews ReleaseBristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo(TM) plus Yervoy(TM) in Advanced Melanoma
2024-09-12 06:59U:BMYNews ReleaseBristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024
2024-09-10 17:45U:BMYNews ReleaseBristol Myers Squibb Announces Dividend
2024-09-09 06:59U:BMYNews ReleaseBristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
2024-09-01 03:33U:BMYNews ReleaseLong-Term Follow-Up Data from Phase 3 Study of CAMZYOS(TM) (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
2024-08-27 06:59U:BMYNews ReleaseBristol Myers Squibb to Participate in Upcoming Investor Conferences
2024-08-26 06:59U:BMYNews ReleaseBristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
2024-08-21 06:59U:BMYNews ReleaseBristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
2024-08-19 06:59U:BMYNews ReleaseEuropean Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
2024-07-26 06:59U:BMYNews ReleaseBristol Myers Squibb Reports Second Quarter Financial Results for 2024
2024-07-25 09:46U:BMYNews ReleaseBristol Myers Squibb Promotes Health Equity with 100 Percent of Marketed Products Now Supported by Access Plans
2024-07-22 09:46U:BMYNews ReleaseBristol Myers Squibb's Commitment to Environment, Social and Governance: Our Progress & Aspirational Goals
2024-07-18 09:20U:BMYNews ReleaseBristol Myers Squibb Reaches Major Milestone in Environmental Sustainability
2024-07-08 06:59U:BMYNews ReleaseBristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day
2024-06-28 15:41U:BMYNews ReleaseBristol Myers Squibb Named to Dow Jones Sustainability Index North America